teaser
Bayer HealthCare has announced that new data from the clinical development programme supporting its oral anticoagulant rivaroxaban will be presented at the 62nd American College of Cardiology (ACC) Annual Scientific Session and Exposition in San Francisco, CA, US, March 9-11, 2013.
These data will provide new information and further insights regarding the potential benefits of rivaroxaban in protecting patients at risk of dangerous blood clots in the arterial thromboembolic setting, including more complete patient protection in the secondary prevention of acute coronary syndrome (ACS) compared to standard treatment and prevention of stroke in people with non-valvular atrial fibrillation (AF).
Notable data analyses to be presented at ACC.13 include*:
- Rivaroxaban Reduces Spontaneous and Large Myocardial Infarctions: Findings from the ATLAS ACS 2-TIMI 51 Trial
– Oral Presentation: 901-5; ACS: New Agents and Approaches
– Saturday, March 9, 2013; 8:30-8:45 am; West, Room 3001
- Rivaroxaban in the Setting of Continued Dual Antiplatelet Therapy: Findings from the ATLAS ACS 2-TIMI 51 Trial
– Oral Presentation: 901-6; ACS: New Agents and Approaches
– Saturday, March 9, 2013; 8:45-9:00 am; West, Room 3001
- Outcomes of Temporary Interruptions of Rivaroxaban or Warfarin in Patients with Atrial Fibrillation in the ROCKET AF Trial
– Oral Presentation: 914-5; Joint Session of the Heart Rhythm Society and the American College of Cardiology: Anticoagulation in Atrial Fibrillation – Management Questions with New Anticoagulants
– Sunday, March 10, 2013; 8:30-8:45 am; West, Room 3009
Full data from ATLAS ACS 2-TIMI 51 were presented at the American Heart Association (AHA) Scientific Sessions meeting in 2011 and were simultaneously published in the New England Journal of Medicine (NEJM). Rivaroxaban has been submitted for marketing authorisation to reduce cardiovascular events in patients with ACS in more than 40 countries, including Europe and the US.
Full data from ROCKET AF were presented at the AHA Scientific Sessions meeting in 2010 and were published in the New England Journal of Medicine (NEJM) in September 2011. Once-daily rivaroxaban has received marketing authorisation for the prevention of stroke and systemic embolism in patients with non-valvular AF in more than 80 countries worldwide, including the EU, the US and Japan.
GARFIELD and ORBIT-AF registry data to be presented
Independently, the Thrombosis Research Institute (TRI) will present data from the ongoing Global Anticoagulant Registry in the FIELD (GARFIELD), providing real-world clinical insights into current anticoagulation therapies in AF management. The GARFIELD Registry is an academic research initiative, led by the TRI and a multi-disciplinary Steering Committee and supported by an unrestricted educational grant from Bayer Pharma AG.
In addition, Duke Clinical Research Institute will present new data on the ORBIT-AF Registry – a multicentre, prospective, outpatient, disease Registry of patients with incident or prevalent AF that will analyse treatment patterns and outcomes in patients with AF in the US The Registry began in June 2010,led by Duke Clinical Research Institute, and is a nationwide collaboration of healthcare providers, with a focus on the optimisation of outpatient management of patients with AF. ORBIT-AF is supported by an independent research grant from Janssen Scientific Affairs, LLC.
- Atrial Fibrillation Treatment Paradox: Characteristics of and First-Year Events in Patients Not Treated with Vitamin-K Antagonists Compared to Treated Patients.
The GARFIELD Registry
– Poster Presentation: 1237-49; Arrhythmias: AF/SVT VIII
– Sunday, March 10, 2013; 3:45-4:30 pm; Expo North
- Quality of Care, Symptoms, and 1 year Outcomes for Women vs. Men with Atrial Fibrillation: Primary Results from the ORBIT-AF Registry
– Late Breaker – Symposium Session 751. Featured Clinical Research II: General Cardiology
– Sunday, March 10, 2013; 5:48-6:00 pm; West, Room 2001
*Abstracts will be available online on the ACC Scientific Session Website as of Thursday, March 7 at 8am PST
